Veloxis Pharmaceuticals AS (VELO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Veloxis Pharmaceuticals AS (VELO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10036
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company developed ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients. ENVARSUS is developed based on the company’s proprietary, patented drug delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis out licensed the commercial rights of Envarsus MENA region, Canada and China. The company sells ENVARSUS XR to wholesalers, specialty pharmacies and other customers. Veloxis is headquartered in Copenhagen, Denmark.

Veloxis Pharmaceuticals AS (VELO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Veloxis Pharma Raises USD60 Million in Debt Financing 10
Private Equity 11
Veloxis Raises USD60 Million in Private Placement of Notes 11
Partnerships 12
Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 12
Licensing Agreements 13
Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 13
Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 14
Taiba Pharma Enters into Licensing Agreement with Veloxis Pharma 15
Equity Offering 16
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 16
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 17
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 18
Veloxis Pharma Raises USD0.6 Million in Private Placement of Shares 19
Veloxis Pharmaceuticals A/S – Key Competitors 20
Veloxis Pharmaceuticals A/S – Key Employees 21
Veloxis Pharmaceuticals A/S – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Aug 13, 2018: Veloxis Pharmaceuticals announces financial results for the first six months of 2018 23
May 14, 2018: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018 24
Feb 27, 2018: Veloxis Pharmaceuticals Releases Annual Report for 2017 25
Nov 14, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2017 26
Aug 16, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017 27
May 16, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2017 28
Feb 28, 2017: Veloxis Pharmaceuticals Releases Annual Report for 2016 29
Corporate Communications 30
Oct 31, 2018: Ira Duarte promoted to chief financial officer of Veloxis Pharmaceuticals 30
Sep 24, 2018: Morten Marott Steps Down as Chief Financial Officer of Veloxis Pharmaceuticals 31
Apr 03, 2018: Veloxis Appoints Morten Marott as Chief Financial Officer 32
Sep 20, 2017: Alastair McEwan Steps Down as Chief Operating Officer of Veloxis Pharmaceuticals 33
Sep 13, 2017: Veloxis Pharmaceuticals Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Veloxis Pharmaceuticals A/S, Deals By Therapy Area, 2012 to YTD 2018 8
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Veloxis Pharma Raises USD60 Million in Debt Financing 10
Veloxis Raises USD60 Million in Private Placement of Notes 11
Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 12
Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 13
Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 14
Taiba Pharma Enters into Licensing Agreement with Veloxis Pharma 15
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 16
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 17
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 18
Veloxis Pharma Raises USD0.6 Million in Private Placement of Shares 19
Veloxis Pharmaceuticals A/S, Key Competitors 20
Veloxis Pharmaceuticals A/S, Key Employees 21
Veloxis Pharmaceuticals A/S, Subsidiaries 22

List of Figures
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Veloxis Pharmaceuticals AS (VELO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Amer Sports Corporation:企業の戦略・SWOT・財務情報
    Amer Sports Corporation - Strategy, SWOT and Corporate Finance Report Summary Amer Sports Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Future Consumer Ltd (FCONSUMER):企業の財務・戦略的SWOT分析
    Future Consumer Ltd (FCONSUMER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • KNM Group Bhd (KNM):石油・ガス:M&Aディール及び事業提携情報
    Summary KNM Group Bhd (KNM Group) is a manufacturer of custom designed process equipment's and modular systems. The company's product portfolio includes gas waste heat recovery systems, process and pressure vessels, quench coolers, scraped surface exchangers, heat transfer equipment, membrane techno …
  • The Coca-Cola Co:企業のM&A・事業提携・投資動向
    The Coca-Cola Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Coca-Cola Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Concho Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Concho Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Concho Resources Inc (Concho) is an oil and gas company that acquires, develops and explores oil and natural gas properties. The company owns and operates exploration assets in the Permian Basin …
  • Medicom Innovation Partner as-医療機器分野:企業M&A・提携分析
    Summary Medicom Innovation Partner a/s (Medicom), formerly Bang & Olufsen Medicom, a subsidiary of Phillips-Medisize Corp, is a medical device company that develops electronic-based drug delivery and connected health systems. The company offers services such as device strategy and direction, device …
  • O’Reilly Automotive, Inc.:企業の戦略・SWOT・財務情報
    O'Reilly Automotive, Inc. - Strategy, SWOT and Corporate Finance Report Summary O'Reilly Automotive, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Gardner Denver Holdings, Inc. (GDI):企業の財務・戦略的SWOT分析
    Gardner Denver Holdings, Inc. (GDI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • East Japan Railway Co:戦略・SWOT・企業財務分析
    East Japan Railway Co - Strategy, SWOT and Corporate Finance Report Summary East Japan Railway Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • MediPal Holdings Corp:企業の戦略・SWOT・財務情報
    MediPal Holdings Corp - Strategy, SWOT and Corporate Finance Report Summary MediPal Holdings Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Cell Source Inc (CLCS):製薬・医療:M&Aディール及び事業提携情報
    Summary Cell Source Inc (Cell Source), formerly Ticket to See Inc, is a biotechnology company that offers development of cell therapy treatments based on the management of immune tolerance. The company’s Veto Cells are white blood cells taken from either the patient or a healthy third-party donor an …
  • Bruel & Kjaer Sound & Vibration Measurement AS:企業の戦略・SWOT・財務情報
    Bruel & Kjaer Sound & Vibration Measurement AS - Strategy, SWOT and Corporate Finance Report Summary Bruel & Kjaer Sound & Vibration Measurement AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Itochu Enex Co Ltd (8133):企業の財務・戦略的SWOT分析
    Itochu Enex Co Ltd (8133) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Black & Veatch Holding Company:企業の戦略・SWOT・財務分析
    Black & Veatch Holding Company - Strategy, SWOT and Corporate Finance Report Summary Black & Veatch Holding Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • EVN AG (EVN):企業の財務・戦略的SWOT分析
    EVN AG (EVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Emzor Pharmaceutical Industries Ltd:企業の戦略的SWOT分析
    Emzor Pharmaceutical Industries Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • John Keells Hotels Plc
    John Keells Hotels Plc - Strategy, SWOT and Corporate Finance Report Summary John Keells Hotels Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Burwill Holdings Limited:企業のM&A・事業提携・投資動向
    Burwill Holdings Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Burwill Holdings Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • B3 S.A.:企業の戦略・SWOT・財務分析
    B3 S.A. - Strategy, SWOT and Corporate Finance Report Summary B3 S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Human Care HC AB:企業の戦略的SWOT分析
    Human Care HC AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆